Renmai Bio Secures Nearly RMB 100 Million in Additional Funding from Top-Tier Investors

VCBeat (WeChat ID: vcbeat) has recently learned that Nanjing Renmai Biotechnology Co., Ltd. (hereinafter referred to as “Renmai Bio”) has secured additional investment from top-tier institutional investors, following its financing round in July backed by Haibang Investment, BGI Win-Win, and Probe New Medical Fund. The total amount raised in this round approached RMB 100 million, with Probe Capital serving as the exclusive financial advisor.

Renmai Bio will primarily allocate the funds from this financing round to the following areas:

In July this year, Renmai Biotech entered into a strategic partnership with Roche Diagnostics China (hereinafter referred to as “Roche Diagnostics”), an international giant in the in vitro diagnostics industry. The collaboration is currently progressing smoothly, with Renmai Biotech having completed the first batch of instrument shipments to Roche Diagnostics in September. Renmai Biotech will further expand its production capacity to ensure the high-quality and timely advancement of its strategic cooperation with Roche Diagnostics.

Renmai Bio MCL60 Production Workshop

Renmai Biotech’s “Growth and Development 3+1 Panel” (GH, IGF-I, IGFBP-3 + 25-OH VD) supports testing of fingerstick blood, serum, and plasma samples, simultaneously meeting the clinical laboratory needs for screening, diagnosis, and treatment monitoring of pediatric growth and development.

It is reported that since obtaining certification for the “3+1 Growth and Development Testing” program in July this year, Renmai Bio has installed its systems in numerous top-tier children’s hospitals and maternal and child health hospitals across China, with many more hospitals awaiting installation and implementation. Meanwhile, Renmai Bio is collaborating with several hospitals, including Tongji Hospital in Wuhan, Shanghai Children’s Hospital, and Nanjing Children’s Hospital, to conduct research projects related to pediatric growth and development.

Renmai Biotechnology will utilize the funds from this financing round to further intensify clinical research and application of its “3+1 Growth and Development Test.”

Renmai Biotech’s “3+1 Growth and Development Test”

In addition to continuing to strengthen innovative research in the field of quantitative immunoassay, Renmai Biotechnology will also utilize the proceeds from this financing round to conduct R&D on new products and platforms in the life sciences sector, thereby expanding into new business segments within life sciences.

At this stage, Renmai Biotechnology has entered a period of rapid development for its proprietary products. Renmai Biotechnology will continue to accelerate product innovation and market channel expansion, striving to become one of the leading brands in China.